Kimia Therapeutics Inc. has disclosed new ATP-dependent RNA helicase A (DHX9) inhibitors potentially useful for the treatment of cancer, autoimmune and viral infections.
Nanjing Synnocare Pharmaceutical Technology Co. Ltd. and Shanghai Synnocare Biopharmaceuticals Co. Ltd. have patented ATP-dependent RNA helicase A (DHX9) inhibitors with potential for use in the treatment of cancer, autoimmune and viral infections.
Impact Therapeutics Inc. has divulged heteroaryl compounds acting as ATP-dependent RNA helicase A (DHX9) inhibitors intended for use in the treatment of cancer.
Elevated expression of DHX9 has been reported in multiple cancer types and it is associated with poor prognosis. In a recently published study, researchers from Accent Therapeutics Inc. evaluated the role of DHX9 in cancer using the tool compound ATX-968, designed as a potent and selective small-molecule inhibitor of DHX9.
Accent Therapeutics Inc. has completed a $75 million series C financing to support progression of its lead programs through early clinical development.
ATP-dependent RNA helicase A (DHX9) inhibitors have been reported in an Accent Therapeutics Inc. patent as potentially useful for the treatment of cancer.
